Effect of the preventive-therapeutic administration of melatonin on mammary tumour-bearing animals

Molecular and Cellular Biochemistry

Volumn 268, Issue 1-2, 2005, Pages 25-31

  Saez, M C ^a   Barriga, C ^a   Garcia, J J ^a   Rodriguez A B ^a   Ortega, E ^a  

^a UNIVERSITY OF EXTREMADURA   (Spain)

Author keywords

DMBA; Immune and neuroendocrine parameters; Mammary tumour; Melatonin; Survival time

Indexed keywords

CATECHOLAMINE DERIVATIVE; DIMETHYLBENZ[A]ANTHRACENE; MELATONIN; PROLACTIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CARCINOGENESIS; BREAST TUMOR; CANCER CHEMOTHERAPY; CANCER PREVENTION; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; DRUG DOSE REGIMEN; FEMALE; HOST RESISTANCE; IMMUNOCOMPETENT CELL; LATENT PERIOD; LYMPHOCYTE COUNT; MACROPHAGE; NATURAL KILLER CELL; NEUROENDOCRINE SYSTEM; NONHUMAN; NORMAL VALUE; PHAGOCYTOSIS; PROLACTIN BLOOD LEVEL; RAT; RAT STRAIN; REGULATORY MECHANISM; RISK FACTOR; SURVIVAL TIME; TUMOR IMMUNITY;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; FEMALE; INJECTIONS, INTRAPERITONEAL; KILLER CELLS, NATURAL; MACROPHAGES; MAMMARY NEOPLASMS, EXPERIMENTAL; MELATONIN; RATS; RATS, SPRAGUE-DAWLEY; SURVIVAL RATE;

EID: 14244253088     PISSN: 03008177     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11010-005-2994-3     Document Type: Article

References (41)

1. Russo IH, Russo J: Mammary gland neoplasia in long-term rodent studies. Environ Health Perspect 104: 938-967, 1996
2. Bartsch C, Bartsch H: Melatonin in cancer patients and in tumor-bearing animals. Adv Exp Med Biol 467: 247-264, 1999
3. Blask DE, Sauer LA, Dauchy RT: Melatonin as a chronobiotic/ anticancer agent: Cellular, biochemical, and molecular mechanisms of action and their implications for circadian-based cancer therapy. Curr Top Med Chem 2: 113-132, 2002
4. Lissoni P, Malugani F, Malysheva O, Kozlov V, Laudon M, Conti A, Maestroni G: Neuroimmunotherapy of untreatable metastatic solid tumours with subcutaneous low-dose interleukin-2, melatonin and naltrexone: Modulation of interleukin-2-induced antitumour immunity by blocking the opioid system. Neuroendocrinol Lett 23: 341-344, 2002
5. Mediavilla MD, San Martin M, Sanchez-Barcelo EJ: Melatonin inhibits mammary gland development in female mice. J Pineal Res 13: 13-19, 1992
6. Currier NL, Sun LZ, Miller SC: Exogenous melatonin: Quantitative enhancement in vivo of cells mediating non-specific immunity. J Neuroimmunol 104: 101-108, 2000. 10.1016/S0165-5728(99)00271-4
7. Pioli C, Caroleo MC, Nistico G, Doria G: Melatonin increases antigen presentation and amplifies specific and non specific signals for T-cell proliferation. Int J Immunopharmacol 15: 463-468, 1993. 10.1016/ 0192-0561(93)90060-C
8. Mhatre MC, Shah PN, Juneja HS: Effect of varying photoperiods on mammary morphology, DNA synthesis, and hormone profile in female rats. J Natl Cancer Inst 72: 1411-1416, 1984
9. Sanchez-Barcelo EJ, Mediavilla MD, Tucker HA: Influence of melatonin on mammary gland growth: In vivo and in vitro studies. Proc Soc Exp Biol Med 194: 103-107, 1990
10. Subramanian A, Kothari L: Melatonin, a suppressor of spontaneous murine mammary tumours. J Pineal Res 10: 136-140, 1991
11. Thyagarajan S, Madden KS, Stevens SY, Felten DL: Anti-tumour effect of L-deprenyl is associated with enhanced central and peripheral neurotransmission and immune reactivity in rats with carcinogen-induced mammary tumours. J Neuroimmunol 109: 95-104, 2000. 10.1016/ S0165-5728(00)00305-2
12. Blask DE, Pelletier DB, Hill SM, Lemus-Wilson A, Grosso DS, Wilson ST, Wise ME: Pineal melatonin inhibition of tumour promotion in the N-nitroso-N-methylurea model of mammary carcinogenesis: Potential involvement of antiestrogenic mechanisms in vivo. J Cancer Res Clin Oncol 117: 526-532, 1991
13. Siegrist C, Benedetti C, Orlando A, Beltran JM, Tuchscherr L, Noseda CM, Brusco LI, Cardinali DP: Lack of changes in serum prolactin, FSH, TSH, and estradiol after melatonin treatment in doses that improve sleep and reduce benzodiazepine consumption in sleep-disturbed, middle-aged, and elderly patients. J Pineal Res 30: 34-42, 2001. 10.1034/ j.1600-079X.2001.300105.x
14. Loscher W, Mevissen M, Haussler B: Seasonal influence on 7,12-dimethylbenz[a]anthracene-induced mammary carcinogenesis in Sprague-Dawley rats under controlled laboratory conditions. Pharmacol Toxicol 81: 265-270, 1997
15. Aoyama H, Mori N, Mori W: Anti-glucocorticoid effects of melatonin on adult rats. Acta Pathol Jpn 37: 1143-1148, 1987
16. Kubatka P, Bojkova B, M Cikova-Kalicka K, Mnichova-Chamilova M, Adamekova E, Ahlers I, Ahlersova E, Cermakova M: Effects of tamoxifen and melatonin on mammary gland cancer induced by N-methyl-N-nitrosourea and by 7,12-dimethylbenz(a)anthracene, respectively, in female Sprague-Dawley rats. Folia Biol (Praha) 47: 5-10, 2001
17. Ortega E, Garcia JJ, Saez MC, De La Fuente M: Changes with aging in the modulation of macrophages by norepinephrine. Mech Ageing Dev 118: 103-114, 2000. 10.1016/S0047-6374(00)00160-3
18. Pinilla L, Gonzalez LC, Tena-Sempere M, Aguilar E: Interactions between serotoninergic and aminoacidergic pathways in the control of PRL secretion in prepubertal male rats. J Physiol Biochem 57: 237-244, 2001
19. Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53: 457-481, 1958
20. Cos S, Garijo F, Corral J, Mediavilla MD, Sanchez-Barcelo EJ: Histopathologic features of DMBA-induced mammary tumours in blind-underfed, blind-anosmic, and blind cold-exposed rats: Influence of the pineal gland. J Pineal Res 6: 221-231, 1989
21. Anisimov NV: The role of pineal gland in breast cancer development. Crit Rev Oncol Hematol 46: 221-234, 2003
22. Reiter RJ, Tan DX, Sainz RM, Mayo JC, Lopez-Burillo S: Melatonin: Reducing the toxicity and increasing the efficacy of drugs. J Pharm Pharmaco 154: 1299-1321, 2002
23. Maestroni GJ, Covacci V, Conti A: Hematopoietic rescue via T-cell-dependent, endogenous granulocyte-macrophage colony-stimulating factor induced by the pineal neurohormone melatonin in tumour-bearing mice. Cancer Res 54: 2429-2432, 1994
24. Morrey KM, Mclachlan JA, Serkin CD, Bakouche O: Activation of human monocytes by the pineal hormone melatonin. J Immunol 153: 2671-2680, 1994
25. Skene DJ, Bojkowski CJ, Currie JE, Wright J, Boulter PS, Arendt J: 6-sulphatoxymelatonin production in breast cancer patients. J Pineal Res 8: 269-276, 1990
26. EJ Sanchez-Barcelo S Cos MD Mediavilla 1988 Influence of pineal gland function on the initiation and growth of hormone-dependent breast tumours. Possible mechanisms In: D. Gupta A. Attanasio R.J. Reiter (eds) The Pineal Gland and Cancer Brain Research Promotion Tübingen 221-232
27. Mockova K, Mnichova M, Kubatka P, Bojkova B, Ahlers I, Ahlersova E: Mammary carcinogenesis induced in Wistar:hAn rats by the combination of ionizing radiation and dimethylbenz(a)anthracene: Prevention with melatonin. Neoplasma 47: 227-229, 2000
28. Brzezinski A: Melatonin in humans. N Engl J Med 336: 186-195, 1997. 10.1056/NEJM199701163360306
29. Garcia-Perganeda A, Guerrero JM, Rafii-EL-Idrissi M, Paz Romero M, Pozo D, Calvo JR: Characterization of membrane melatonin receptor in mouse peritoneal macrophages: Inhibition of adenylyl cyclase by a pertussis toxin-sensitive G protein. J Neuroimmunol 95: 85-94, 1999
30. Toujas L, Delcros JG, Diez E, Gervois N, Semana G, Corradin G, Jotereau F: Human monocyte-derived macrophages and dendritic cells are comparably effective in vitro in presenting HLA class I-restricted exogenous peptides. Immunology 91: 635-642, 1997
31. Poon AM, Liu ZM, Pang CS, Brown GM, Pang SF: Evidence for a direct action of melatonin on the immune system. Biol Signals 3: 107-117, 1994
32. Kishi A, Takamori Y, Ogawa K, Takano S, Tomita S, Tanigawa M, Niman M, Kishida T, Fujita S: Differential expression of granulysin and perforin by NK cells in cancer patients and correlation of impaired granulysin expression with progression of cancer. Cancer Immunol Immunother 50: 604-614, 2002
33. Nannmark U, Basse P, Johansson BR, Kuppen P, Kjergaard J, Hokland M: Morphological studies of effector cell-microvessel interactions in adoptive immunotherapy in tumour-bearing animals. Nat Immun 15: 78-86, 1996-97
34. Welsch CW: Host factors affecting the growth of carcinogen-induced rat mammary carcinomas: A review and tribute to Charles Brenton Huggins. Cancer Res 45: 3415-3443, 1985
35. Meites J: Relation of the neuroendocrine system to the development and growth of experimental mammary tumours. J Neural Transm 48: 25-42, 1980
36. Harada Y: Pituitary role in the growth of metastasizing MRMT-1 mammary carcinoma in rats. Cancer Res 36: 18-22, 1976
37. Takahashi M, Iizuka S, Watanabe T, Midori Y, Ando J, Wakabayashi K, Maekawa A: Possible mechanisms underlying mammary carcinogenesis in female Wistar rats by nitrofurazone. Cancer Lett 156: 177-184, 2000
38. Pasqualini C, Bojda F, Kerdelhue B: In vitro estrogen-like effects of 7,12-dimethylbenz(a)anthracene on anterior pituitary dopamine receptors of rats. Cancer Res 48: 6434-6437, 1988
39. Pasqualini C, Sarrieau A, Dussaillant M, Corbani M, Bojda-Diolez F, Rostene W, Kerdelhue B: Estrogen-like effects of 7,12-dimethylbenz(a)anthracene on the female rat hypothalamo-pituitary axis. J Steroid Biochem 36: 485-491, 1990
40. Patel DD, Bhatavdekar JM, Chikhlikar PR, Ghosh N, Suthar TP, Shah NG, Mehta RH, Balar DB: Node negative breast carcinoma: Hyperprolactinemia and/or overexpression of p53 as an independent predictor of poor prognosis compared to newer and established prognosticators. J Surg Oncol 62: 86-92, 1996
41. Strungs I, Gray RA, Rigby HB, Strutton G: Two case reports of breast carcinoma associated with prolactinoma. Pathology 29: 320-323, 1997. 1:STN:280:ByiH3Mjgslw%3D